Lipid formulations of amphotericin

被引：13
|
作者：
Botero, Martha C. [1 ]
Puentes-Herrera, Marcela [1 ]
Cortes, Jorge A. [2 ]
机构：
[1] Univ Nacl Colombia, Fac Med, Dept Med Interna, Bogota, Colombia
[2] Univ Nacl Colombia, Grp Invest Enfermedades Infecciosas, Bogota, Colombia
来源：
REVISTA CHILENA DE INFECTOLOGIA | 2014年 / 31卷 / 05期
关键词：
Amphotericin B; fungemia; drug toxicity; histoplasmosis; aspergillosis; candidemia; candidiasis; invasive; cryptococcosis; zygomycosis; leishmaniasis; MULTICENTER RANDOMIZED-TRIAL; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; HEMATOLOGIC MALIGNANCIES; DOUBLE-BLIND; VISCERAL LEISHMANIASIS; INVASIVE ASPERGILLOSIS; ANTIFUNGAL THERAPY; SALVAGE THERAPY; B AMBISOME;
D O I：
10.4067/S0716-10182014000500002
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. This drug is associated with a high rate of side effects, especially renal toxicity. Lipid formulations (liposomal, lipid complex, colloidal suspension and the Indian liposomal formulation) have been developed, which share the same antifungal spectrum but differ in efficacy and toxicity. A review of amphotericin lipid formulations is presented, focusing on differences in efficacy and, especially renal toxicity. The main problem for use of these formulations in Latin America is their highcost.
引用
收藏
页码：518 / 527
页数：10
相关论文
共 50 条
  • [31] Lipid amphotericin B formulations as comparators in clinical trials - Reply
    Ostrosky-Zeichner, L
    Marr, KA
    Rex, JH
    Cohen, SH
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) : 306 - 307
  • [32] Investigating the impact of lipid formulations on the aggregation and behavior of amphotericin B
    Lewis, Taylor
    Higgins, Kevin
    Sarabia, Grace
    Calhoun, Tessa
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [33] The use of lipid formulations of amphotericin B for systemic fungal infections
    Leenders, ACAP
    deMarie, S
    LEUKEMIA, 1996, 10 (10) : 1570 - 1575
  • [34] Lipid formulations of amphotericin B: Recent progress and future directions
    Hiemenz, JW
    Walsh, TJ
    CLINICAL INFECTIOUS DISEASES, 1996, 22 : S133 - S144
  • [35] Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis
    Sidhu, Ritam
    Lash, David B.
    Heidari, Arash
    Natarajan, Piruthiviraj
    Johnson, Royce H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (07)
  • [36] LIPID-BASED FORMULATIONS OF AMPHOTERICIN-B - REPLY
    MOREAU, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (05) : 711 - 711
  • [37] Lipid formulations of amphotericin B treatment for neonatal systemic candidiasis
    Krebs, VLJ
    Diniz, EMA
    Ceccon, MEJ
    Giolo, CRM
    Vaz, FAC
    2ND INTERNATIONAL CONGRESS ON NEW TECHNOLOGIES IN REPRODUCTIVE MEDICINE, NEONATOLOGY AND GYNECOLOGY, 1999, : 527 - 530
  • [38] Severe hepatic injury associated with lipid formulations of amphotericin B
    Ellis, M
    Shamoon, A
    Gorka, W
    Zwaan, F
    al-Ramadi, B
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) : E87 - E89
  • [39] Controlled trials of amphotericin B lipid complex and other lipid-associated formulations
    Winston, DJ
    Schiller, GJ
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) : 236 - 237
  • [40] CONCENTRATIONS AND ACTIVITY OF AMPHOTERICIN B IN BILE ACHIEVED BY LIPID-FORMULATIONS
    Welte, R.
    Eschertzhuber, S.
    Leitner-Rupprich, S.
    Aigner, M.
    Lass-Floerl, C.
    Weiler, S.
    Stienecke, E.
    Bellmann-Weiler, R.
    Joannidis, M.
    Bellmann, R.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E90 - E90
12345